The EpiPen Era
Is Ending.
Al(:betta Begins.

The world's first anxiety-free epinephrine auto-injector. 100% bioavailability[7]. Zero needle visibility. Engineered for the panic moment — and a $3.5B market[6] ready to switch.

Request a Briefing See the Crisis
ISO 13485 Engineering• 46+ Patents Pending• 100% Bioavailability
Al(:betta auto-injector device
600K[1]
ER visits / year
1 every minute
70%[2]
Of fatal cases
Device unavailable or delayed
56%[3]
Caregiver fear
Won't inject their child
43%[4]
Don't carry it
Of prescribed devices
60s[5]
Golden window
Before irreversible damage
$3.5B[6]
Market by 2034
8.8% CAGR
100%[7]
Bioavailability
IM-grade certainty
2044[8]
Patent moat
18+ yrs exclusivity
Sources & References
  1. [1]CDC National Hospital Ambulatory Medical Care Survey (NHAMCS), 2022; Clark S, et al. J Allergy Clin Immunol Pract (2023) — anaphylaxis-related ER visits in the United States.
  2. [2]Turner PJ, Gowland MH, et al. "Fatal anaphylaxis: mortalities and risk factors." J Allergy Clin Immunol Pract. 2017;5(5):1169–1178; Greenberger PA. "Fatal anaphylaxis and the role of epinephrine."
  3. [3]Lent Innovations proprietary market research — Caregiver Survey, 2024; consistent with Capucilli P, et al. Ann Allergy Asthma Immunol on caregiver hesitation.
  4. [4]FARE (Food Allergy Research & Education) patient survey data on non-carriage rates, 2023; published epinephrine auto-injector adherence studies, J Allergy Clin Immunol.
  5. [5]Simons KJ, Simons FE. "Epinephrine and its use in anaphylaxis: current and future prospects." J Allergy Clin Immunol Pract — onset of therapeutic action within 60 seconds of IM administration.
  6. [6]Grand View Research — "Epinephrine Auto-Injector Market Size, Share & Trends Analysis Report, 2024–2034"; analyst consensus (William Blair, Raymond James, Cantor Fitzgerald), Dec 2025.
  7. [7]Simons FE, Gu X, Simons KJ. "Epinephrine absorption after intramuscular injection." J Allergy Clin Immunol. 2001;108(5):871–873 — establishing 100% IM epinephrine bioavailability.
  8. [8]USPTO Patent Application Publication US20250025638A1 — filed July 2024; expiration July 2044 per 35 U.S.C. §154; Lent Innovations patent docket.
Anaphylaxis

Anaphylaxis Is Escalating —
And the System Is Failing

Anaphylaxis is a life-threatening emergency with a 60-second window[2]. Current solutions are broken — and the data is unambiguous.

Mother in distress during child's allergic emergency
The 60-Second Window

A mother stares at the device that could save her child — and freezes.

Anaphylaxis cascade inside the human body
The Internal Storm

Histamine cascade, airway constriction, cardiovascular collapse — all within minutes[2].

Emergency Volume
0K[1]
Annual ER visits for anaphylaxis — tripled in the last decade
≈ 1 ER visit every minute
Fatal Compliance Gap
0%[2]
Of fatal anaphylaxis cases — medication was unavailable or administration was delayed
Preventable deaths
Prescription Gap
≈0%[3]
Increase in "lost patients" — the gap between Rx written and Rx filled — over the last 10 years
Systemic failure
Adult Prevalence
0M[4]
U.S. adults living with food allergies — 1 in every 11 people. 25% developed their allergy after age 18
1 in 11 adults
Pediatric Prevalence
0M[5]
U.S. children with food allergies — 1 in 13. Teens 15–24 have the highest mortality rate from anaphylaxis
2 per classroom
Caregiver Fear Index
0%[6]
Of caregivers fear using a needle-based auto-injector on their child — driving dangerous non-compliance
Fear drives non-use
"

Paradoxically, long-term patients were MORE likely to fail than new users — proving current designs are fundamentally broken.[3]

Source: Lent Innovations proprietary market research — Immunology Practice Survey, 2024/2025

Sources & References
  1. [1]CDC National Hospital Ambulatory Medical Care Survey (NHAMCS), 2022; trend analysis per Clark S, et al. J Allergy Clin Immunol Pract (2023) on anaphylaxis-related emergency department visits in the United States.
  2. [2]Turner PJ, Gowland MH, et al. "Fatal anaphylaxis: mortalities and risk factors." J Allergy Clin Immunol Pract. 2017;5(5):1169–1178; Greenberger PA. "Fatal anaphylaxis and the role of epinephrine." J Allergy Clin Immunol Pract.
  3. [3]Lent Innovations proprietary market research — Immunology Practice Survey, 2024–2025. Analysis of prescription-to-fill conversion data across U.S. allergy practices.
  4. [4]Gupta RS, et al. "Prevalence and Severity of Food Allergies in US Adults." JAMA Network Open. 2019;2(1):e185630; FARE (Food Allergy Research & Education) prevalence data, 2024.
  5. [5]Gupta RS, et al. "Prevalence and Severity of Food Allergies in US Children." Pediatrics. 2018;142(6):e20181235; FARE (Food Allergy Research & Education) prevalence data, 2024; teen mortality per Turner PJ, et al. (2017).
  6. [6]Lent Innovations proprietary market research — Caregiver Survey, 2024; consistent with published caregiver hesitation data in Capucilli P, et al. Ann Allergy Asthma Immunol.
The Case for Change

A Broken Standard of Care.
A Definitive Answer.

Anaphylaxis is a 60-second emergency served by devices patients fear and refuse to use. The unmet need is not incremental — it is structural. Al(:betta is the first device built to close it.

The standard of care has failed patients for a generation. Al(:betta is built to replace it — certainty without compromise, usability without trade-offs.

Request a Briefing

Important Disclosure & Disclaimers

Investigational Device. Al(:betta is an investigational auto-injector in development by Lent Innovations, LLC. It has not been approved or cleared by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority worldwide. It is not commercially available, is not approved for any medical use, and may not be prescribed, sold, or administered. All statements regarding safety, efficacy, bioavailability, or clinical performance are preliminary, based on development-stage data and published literature, and are not a guarantee of any future regulatory outcome or product performance.

Not an Offer of Securities. Nothing on this website constitutes, or should be construed as, an offer to sell, or a solicitation of an offer to buy, any security, equity, debt, or financial instrument. Any offering of securities, if and when made, will be made only to qualified institutional and accredited investors pursuant to definitive offering documents and applicable exemptions from registration under the U.S. Securities Act of 1933, as amended, and other applicable securities laws. No offering is being made hereby, and no obligation to make any offering exists.

Forward-Looking Statements. This website contains forward-looking statements, projections, estimates, and market forecasts that involve significant risks and uncertainties. Actual results, performance, market size, regulatory outcomes, and commercial prospects may differ materially. Past performance of comparable companies or products is not indicative of future results. No representation or warranty, express or implied, is made as to the accuracy or completeness of any information herein.

Not Medical Advice. Nothing on this website constitutes medical advice, clinical guidance, or a recommendation for any treatment. Patients and caregivers should consult a qualified healthcare professional regarding any medical condition or treatment.

Confidential & Restricted Audience. This content is intended exclusively for institutional investors, strategic partners, and qualified financial professionals — not for patients, the general public, or retail investors. The information is confidential and may not be reproduced, redistributed, or relied upon by any other party. All market data and clinical statistics are sourced from publicly available information and proprietary research; sources are cited above. © 2026 Lent Innovations, LLC. All Rights Reserved.

Al(:betta

The Certainty of Injection.
The Ease of Innovation.

© 2026 Lent Innovations, LLC. All Rights Reserved.

IMPORTANT DISCLAIMER: This website and all associated materials are intended exclusively for institutional investors, strategic partners, accredited investors, and qualified financial professionals. This content is NOT directed at patients, healthcare providers, caregivers, or the general public.

Al(:betta is an investigational auto-injector device currently in development by Lent Innovations, LLC. It has NOT been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority worldwide. Al(:betta is not commercially available and may not be prescribed or used for any medical purpose.

Nothing on this website constitutes medical advice, clinical guidance, a solicitation for retail investment, or a guarantee of future performance. Financial projections are forward-looking statements subject to significant risk and uncertainty. Past performance of comparable companies is not indicative of future results.

All market data, clinical statistics, and competitive analyses are sourced from publicly available information and proprietary research. Sources are cited where applicable. © 2026 Lent Innovations, LLC. All Rights Reserved. Confidential.

Copyright & Ownership: All material on this website — including but not limited to text, content, images, graphics, logos, device designs, product renderings, clinical data, proprietary research, software, and all other intellectual property — is the exclusive property of Lent Innovations, LLC. No part of this website may be reproduced, distributed, transmitted, displayed, published, or broadcast without the prior written permission of Lent Innovations, LLC. Unauthorized use, reproduction, or distribution of any material herein is strictly prohibited and may violate copyright, trademark, and other intellectual property laws. © 2026 Lent Innovations, LLC. All Rights Reserved.

Sourcing Policy: Every statistic and factual claim on this website is annotated with a superscript reference number. Full source citations are listed in the "Sources & References" block at the bottom of each section. Public sources include peer-reviewed medical literature, FDA prescribing information, SEC filings, USPTO/EPO patent records, and recognized market research firms. Claims labeled "proprietary" are based on Lent Innovations internal research and are available to qualified parties upon request.

IMPORTANT DISCLAIMER: For institutional investors only. Al(:betta is an investigational device — not FDA-approved. Not a solicitation for investment or medical advice. © 2026 Lent Innovations, LLC.